Oscotec Inc. 039200

Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.

Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlocking up to $1 billion in peak U.S. sales potentialOscotec will receive $25.0 million upfront, with future payments tied to development, regulatory, and commercial milestones, as well as tiered royalties on future net salesAgios will host investor conference call and webcast today at 8:00 a.m. ET CA

Recently published Immune Thrombocytopenia Market Insights report includes a comprehensive understanding of current treatment practices, immune thrombocytopenia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of Acute Myeloid Leukemia (AML). Under the terms of the agreement, Yatiri Bio holds the exclusive option to license denfivontinib for development and commercialization. Yatiri Bio’s Pro

As the Asian markets continue to navigate a complex economic landscape, characterized by mixed growth signals and cautious optimism, investors are increasingly looking towards companies with robust insider ownership as potential opportunities. In this context, stocks with strong insider involvement often indicate confidence in the company's future prospects and alignment of interests between management and shareholders, making them appealing for those seeking growth in uncertain times.

As the Bank of Japan raises its benchmark interest rate to a 30-year high and China's economic indicators show mixed signals, the Asian markets are navigating through a period of significant economic shifts. In this evolving landscape, growth companies with substantial insider ownership can offer unique insights into potential resilience and long-term value creation.

As global markets navigate a complex landscape of economic indicators, Asian stocks have shown resilience, particularly in sectors like technology and artificial intelligence. In this environment, growth companies with high insider ownership can signal strong internal confidence and potential alignment with shareholder interests.

As of November 2025, Asian markets have shown resilience amid global economic uncertainties, with easing U.S.-China trade tensions providing a boost to investor sentiment. In this environment, growth companies in Asia with high insider ownership are particularly noteworthy as they often indicate strong confidence from those closely tied to the business, potentially aligning with broader market optimism.

As global markets navigate a period of volatility, with trade tensions and economic uncertainties shaping investor sentiment, Asia's stock markets have been notably impacted by these broader trends. In such an environment, growth companies with strong insider ownership can offer potential stability and alignment of interests between management and shareholders, making them attractive considerations for investors seeking resilience amidst market fluctuations.